Audio Visual Entrainment: What 50 Years of Research Says About Light and Sound for Mental Health

For decades, light and sound stimulation has occupied an unusual position in mental health: clinically studied since the 1980s, used in research labs and private practices around the world, and almost entirely invisible to the general public. That has begun to shift. A 2025 peer-reviewed review from the University of Milan, published in Brain Sciences, surveyed more than 50 years of research on audio visual entrainment and concluded that the technique produces measurable changes in brainwave activity and offers therapeutic potential for anxiety, depression, insomnia, and cognitive performance.

The Milan review arrives at a useful moment. As digital mental health tools proliferate and consumers become more skeptical of meditation apps that promise outcomes without clinical backing, audio visual entrainment — often abbreviated as AVE — represents a category with an unusually long research record but limited consumer awareness.

What audio visual entrainment actually is

Audio visual entrainment refers to the use of rhythmic light and sound stimuli to influence brainwave frequencies. The underlying principle is called frequency-following response: when the brain is exposed to a consistent pulse — flickering light, isochronic tones, binaural beats — neural oscillations tend to synchronize with that pulse. Different frequencies are associated with different states. Slower frequencies in the alpha (8–12 Hz) and theta (4–8 Hz) ranges are linked with relaxation and meditative states. Faster beta frequencies are associated with alertness and focus.

In a clinical AVE session, a person typically wears glasses fitted with LEDs and headphones playing isochronic tones. Sessions usually last between 6 and 30 minutes, and protocols are tailored to the target outcome — different frequency profiles for sleep, for anxiety, for attention, for cognitive performance.

The evidence record

The 2025 University of Milan review is the most comprehensive recent synthesis of AVE research. It covers studies from the 1980s onward and identifies consistent signals across applications: improvements in subjective anxiety scores, reductions in insomnia symptoms, and changes in EEG activity that correspond to the targeted frequencies. The review also explicitly notes the limitations of the literature: many studies are small, methodologies vary, and replication has been inconsistent across labs. Earlier work from the 1980s and 1990s relied on smaller samples and less rigorous controls; more recent studies have improved methodology but still struggle with the blinding problem inherent to a sensory intervention people can plainly feel.

That mixed picture is consistent with the broader digital mental health landscape. A 2024 meta-analysis aggregating 28 systematic reviews and 118,970 participants found that digital interventions produce significant improvements for insomnia, depression, and anxiety, while emphasizing that effect sizes vary widely and engagement remains the central practical challenge — people benefit from these tools only when they actually use them.

How AVE is delivered today

For most of its history, AVE required dedicated hardware: bulky goggles, professional units priced at several hundred dollars, and access through clinicians who specialized in the technique. That access barrier kept AVE confined largely to research and to a small number of private practices.

The arrival of smartphones with high-frequency camera flashes and audio output has changed the delivery model. Several teams have adapted the underlying protocols to use phone hardware: stroboscopic light is delivered through the phone's flash with the user's eyes closed, and isochronic tones come through headphones. 6th Mind is one example of this approach. Built by a Bulgarian psychiatrist and psychologist team whose private practice has documented more than 500 AVE therapy sessions, the app translates the protocols used in their clinic into a free phone-based format. Sessions are 6 or 11 minutes and protocols are generated based on an initial assessment.

Other teams have taken different approaches, from research-grade hardware that remains the gold standard for controlled studies to consumer wearables that emphasize lifestyle framing over clinical positioning. The market is fragmented enough that comparing tools requires reading past the marketing layer to the underlying protocol design.

How AVE compares to other neuromodulation approaches

Within the broader neuromodulation category, AVE sits at the lighter end of the intensity spectrum. Repetitive transcranial magnetic stimulation (rTMS) and electroconvulsive therapy operate at clinical intensities that produce strong direct effects but require specialized equipment, trained operators, and clinical settings. Transcranial direct-current stimulation (tDCS) sits in the middle — non-invasive but still requiring electrodes and conductive gel. AVE, by contrast, works through sensory channels the brain is already accustomed to processing, which is part of what makes home-based delivery feasible.

The trade-off is that the effect sizes are correspondingly modest. The Milan review is clear that AVE should not be confused with clinical-grade neuromodulation; it is closer in profile to mindfulness or breath-work — a low-intensity, accessible practice that produces measurable but bounded effects when used consistently. The people who benefit most are those who pair it with other evidence-based components rather than expecting it to carry the entire load.

What to look for when evaluating an AVE tool

Because AVE sits at the intersection of consumer technology and clinical methodology, evaluation criteria matter. The Milan review and the broader digital mental health literature point to a few questions worth asking before adopting any AVE tool:

• Clinical origin. Was the protocol developed by clinicians who use it with patients, or assembled from generic frequency tables? Tools with documented clinical session counts have a different evidence basis than ones built around generic relaxation playlists.
• Protocol specificity. Does the tool offer different protocols for different conditions, or one generic session repackaged with different labels? AVE research finds that frequency profiles matter — what helps with sleep is not the same as what helps with anxiety.
• Transparency about evidence. Does the tool describe what AVE can and cannot do, or does it promise outcomes the literature does not support?
• Realistic session length and frequency. Clinical AVE protocols typically run 15–30 minutes per session and are used regularly over weeks, not a single 90-second session.

Limitations and when professional care is needed

AVE is not a replacement for psychiatric care. The Milan review is explicit on this point: the technique has shown promise as an adjunct or as a self-help option for sub-clinical symptoms, but it has not been validated as a standalone treatment for severe depression, severe anxiety, bipolar disorder, psychotic disorders, or active suicidal ideation. Anyone experiencing severe or worsening symptoms — particularly thoughts of self-harm — should reach out to a mental health professional or a crisis line, not a phone-based tool.

AVE also has a specific contraindication that consumer-facing tools sometimes underweight: people with epilepsy or photosensitive seizure disorders should not use stroboscopic light protocols without medical guidance. Anyone with a personal or family history of seizures should consult a clinician before trying any flicker-based stimulation.

Finally, AVE works best when used consistently. The literature is clear that one-off sessions produce minimal lasting benefit; the protocols that show effects in studies are typically multi-week. As with any behavioral health intervention, the gap between the evidence base and the everyday user experience often comes down to follow-through.

The broader picture

Audio visual entrainment is neither the breakthrough that some marketing language suggests nor the fringe pseudoscience that skeptics sometimes assume. The 50-year research record reviewed by the Milan group describes a real but modest neurobiological effect with practical applications for relaxation, sleep, and adjunctive symptom management. As phone-based delivery makes the technique accessible to broader populations, the central questions shift from "does AVE do anything" — the literature suggests it does — to "which protocols, at what frequency, for which people, with what expectation-setting." Consumers and clinicians alike are better served by tools that engage with those questions honestly than by ones that flatten the picture into a marketing claim.